Source: International Congress 2017 – Best clinical practice for the management of chronic lung diseases
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Borisov (Moscow, Russian Federation). Pulmonary lesions in patients with inflammatory bowel disease – the baseline and under anti-tumor necrosis factor therapy.. 362

Member's Comments

No comment yet.

Related content which might interest you: Tumor necrosis factor α in chronic pulmonary diseases of children Source: Eur Respir J 2002; 20: Suppl. 38, 193s Year: 2002 Diffuse parenchymal lung inflammation response in patients with inflammatory bowel disease Source: Eur Respir J 2005; 26: Suppl. 49, 540s Year: 2005 Radiographic changes in patients with tumor necrosis factor alpha inhibitor and immunomodulatory drug users: Four years follow up Source: International Congress 2016 – Mixed-up imaging of various chest diseases Year: 2016 Evolution of systemic response in patients with pulmonary sarcoidosis of different course of the disease during anti-inflammatory treatment Source: Annual Congress 2009 - Sarcoidosis in review Year: 2009 Role of systemic inflammation mediated by IL-6 and TNF-alpha cytokines in chronic obstructive pulmonary disease and its progression: A three year follow up study Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases Year: 2013 Rosuvastatin influence on inflammatory and anti-inflammatory cytokines in blood in patients with chronic obstructive pulmonary disease Source: International Congress 2017 – COPD management Year: 2017 Glucocorticosteroid therapy as predisposing factor for pulmonary sarcoidosis relapse Source: International Congress 2018 – Granulomatous disorders: heterogeneous diseases with variable management Year: 2018 Pulmonary involvement of inflammatory bowel disease in children and adult patients Source: Annual Congress 2010 - Respiratory system involvement in non-pulmonary disorders Year: 2010 Tumor necrosis factor-α gene polymorphism and inflammatory process in cystic fibrosis patients Source: Eur Respir J 2005; 26: Suppl. 49, 403s Year: 2005 Evaluation levels of pro-inflammatory cytokines tumour necrosis factor (TNF)-alpha and interferon (IFN)-gamma in lung cancer complicated with metastatic pleurisy Source: Eur Respir J 2001; 18: Suppl. 33, 233s Year: 2001 Should isoniazid prophylaxis be prescribed to the patients under tumor necrosis factor-alpha antagonists independent of tuberculin skin test? Source: International Congress 2015 – Screening strategies in TB Year: 2015 The level of anti-inflammatory cytokine IL-10 in patients with chronic obstructive pulmonary disease of varying severity Source: Annual Congress 2013 –COPD: new markers of diseases Year: 2013 Serum leptin and tumor necrosis factor – alpha levels and maximal exercise performance in patients with chronic obstructive pulmonary disease Source: Annual Congress 2008 - Respiratory muscles in disease Year: 2008 Association of the TNF gene promoter polymorphism with serum tumor necrosis factor-alpha levels in chronic obstructive pulmonary disease patients Source: Eur Respir J 2006; 28: Suppl. 50, 522s Year: 2006 Measurement of tumour necrosis factor converting enzyme (TACE) activity on alveolar macrophages from healthy subjects and subjects with inflammatory lung disease Source: Eur Respir J 2002; 20: Suppl. 38, 417s Year: 2002 Risk of chemotherapy-induced pulmonary fibrosis is associated with polymorphic tumour necrosis factor-a2 gene Source: Eur Respir J 2002; 19: 912-918 Year: 2002 Azithromycin in the treatment of children with chronic inflammatory lung disease (CILD) Source: Eur Respir J 2004; 24: Suppl. 48, 391s Year: 2004 The markers of inflammatory process activity and fybrogenesis activity in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease I Year: 2012 Clinical course of cystic fibrosis lung disease and tumour necrosis factor-β gene polymorphism Source: Annual Congress 2008 - Cystic fibrosis: factors affecting lung health Year: 2008 The use of tumor necrosis factor alpha inhibitor pentoxifylline in the treatment of patients with I and II stages of pulmonary sarcoidosis Source: Eur Respir J 2006; 28: Suppl. 50, 542s Year: 2006